Serotonin signaling suppresses generation of amyloid-b (Ab) in vitro and in animal models of Alzheimer's disease (AD). We show that in an aged transgenic AD mouse model (APP/PS1 plaque-bearing mice), the antidepressant citalopram, a selective serotonin reuptake inhibitor, decreased Ab in brain interstitial fluid in a dose-dependent manner. Growth of individual amyloid plaques was assessed in plaque-bearing mice that were chronically administered citalopram. Citalopram arrested the growth of preexisting plaques and reduced the appearance of new plaques by 78%. In healthy human volunteers, citalopram's effects on Ab production and Ab concentrations in cerebrospinal fluid (CSF) were measured prospectively using stable isotope labeling kinetics, with CSF sampling during acute dosing of citalopram. Ab production in CSF was slowed by 37% in the citalopram group compared to placebo. This change was associated with a 38% decrease in total CSF Ab concentrations in the drug-treated group. The ability to safely decrease Ab concentrations is potentially important as a preventive strategy for AD. This study demonstrates key target engagement for future AD prevention trials.
INTRODUCTION
Alzheimer's disease (AD) is the most common cause of dementia and is characterized pathologically by amyloid plaques and neurofibrillary tangles. A devastating illness, AD typically leads to death within 7 to 8 years of diagnosis and currently affects 5 million patients in the United States (1). AD incidence doubles every 5 years after 65 years of age, and the prevalence is projected to increase markedly in the next decades to between 13.2 and 16 million patients in the United States by mid-century, unless preventive measures are developed (1) . Because asymptomatic participants in a large prospective prevention trial might be exposed to an experimental compound for many years, the compound should have a proven safety record, as is the case for selective serotonin reuptake inhibitor (SSRI) drugs. To date, there have not been drugs with both an established safety profile and a mechanismbased rationale that have been tested in primary or secondary prevention trials of AD.
The accumulation of amyloid-b (Ab) peptide in the brain and its aggregation into amyloid plaques are currently considered the pathological trigger for AD (2) . In humans, cerebrospinal fluid (CSF) Ab concentrations begin changing before tau levels; amyloid deposition occurs in the brain decades before the onset of clinical symptoms (3) (4) (5) . Given that aggregation of the Ab peptide into plaques appears to be concentrationdependent (6, 7) , methods for reducing Ab concentrations are important targets for therapy.
In addition to its effect as an antidepressant, the neurotransmitter serotonin is a candidate for reducing Ab concentrations by reducing Ab production. In depression, the antidepressant drug class SSRIs are thought to have their effect by blocking the reuptake of serotonin into the presynaptic terminals, thus increasing the availability of serotonin. A distinct effect has been demonstrated in many studies showing the link between serotonin, AD, and Ab. Serotonin receptor levels are reduced in human AD brains (8, 9) . Activation of serotonin receptors has been shown to reduce Ab production in vitro; treatment with serotonin or receptor agonists activates intracellular signaling cascades and increases the a-secretase product sAPP-a (10) (11) (12) . Modulating serotonin in vivo shows consistent effects: a single-dose treatment with SSRIs in young APP/PS1 mice reduced Ab concentrations in the brain interstitial fluid (ISF) by 25% (13) . In those studies, serotonin signaling did not alter the rate of Ab clearance, suggesting that reduced Ab production was responsible for lower Ab concentrations. Chronic SSRI treatment over the course of 4 months reduced Ab plaque load by 50% in mice (13) . SSRI treatment in the 3xTg AD mouse model showed similar reductions in Ab (14) . The beneficial effects of serotonin appear to carry into humans as well. Previously depressed patients who had undergone SSRI treatment in the 5 years preceding their enrollment in a positron emission tomography (PET) study to quantify amyloid binding had less evidence of Ab deposits than those who had not been exposed to SSRI treatment (13) .
Here, we first examined the dose-response effects of citalopram, one of the most selective SSRIs for serotonin, on lowering brain Ab concentrations in mice. We also prospectively examined the effect of citalopram on individual plaque growth in the same mouse model of AD. On the basis of these studies, we tested the effects of an approximately equivalent dose of citalopram on human Ab concentrations and production. We used the stable isotope labeling kinetics (SILK) method (15) , which quantifies the amount of newly generated Ab, as well as the rate of production and clearance of Ab, within the CSF in humans. We then examined the hypothesis that, similar to results in the AD transgenic mice, citalopram would prospectively lower Ab production in the human central nervous system (CNS).
RESULTS
In aged APP/PS1 mice citalopram-induced reduction in amyloid is dose dependent Previous studies demonstrated in 3-month-old APP/PS1 +/− mice, an age before Ab pathology, that citalopram (10 mg/kg) reduces brain ISF Ab concentrations by 25% (13) . Here, we determined the acute effect of several doses of citalopram on brain ISF Ab concentrations in 12-month-old, plaque-bearing APP/PS1 mice. Mice were implanted with microdialysis probes into the hippocampus to sample brain ISF over time in awake, behaving animals. ISF was sampled every 90 min for up to 32 hours. Baseline ISF Ab concentrations were established in each mouse over 8 hours, followed by intraperitoneal administration of citalopram or vehicle, and then another 24 hours of ISF sampling (Fig. 1A) . Mice administered citalopram at 2.5 mg/kg had no significant change in ISF Ab concentrations compared to vehicle-treated mice at 24 hours after dosing (Fig. 1B) . At 24 hours after administration, however, there was a significant dose-dependent reduction in ISF Ab at citalopram doses of 5 and 10 mg/kg (mean reduction of 12.4 and 24.5%, respectively, compared to baseline concentrations). The maximum reduction in ISF Ab occurred at 10 mg/kg, because a higher dose of citalopram (20 mg/kg) had no additional effect (27.5% reduction). Plaque load within the hippocampus was assessed histologically in all mice at the 24-hour time point and did not differ between groups (fig. S1). A calculation to determine roughly equivalent doses of citalopram between mice and humans estimated that a dose of 10 mg/kg for a mouse is comparable to 50 mg/day in humans (16), a common, though high, dose of citalopram prescribed to treat depression (17) . Citalopram is one of the most selective SSRIs for serotonin reuptake and has among the most favorable side effect profiles compared with other antidepressants (17) .
Chronic citalopram treatment blocks plaque growth in APP/PS1 mice Using APP/PS1 mice, we examined the effect of chronic citalopram administration on amyloid plaque appearance and growth. Six-month-old APP/PS1 mice were treated with citalopram (10 mg/kg) (n = 8) or vehicle (n = 6) intraperitoneally daily for 28 days. Brains from mice were noninvasively imaged using two-photon microscopy on the day before the initial injection and on the day after the final injection (28 days), focusing on identical high-power fields so that individual plaques could be compared over time. During this 28-day interval, plaques in mice treated with vehicle grew on average 111.4 µm 2 , a growth rate significantly different from 0 (P = 0.0003), whereas plaques in citalopramtreated mice did not grow (−22.4 µm 2 , a growth rate not significantly different from 0; P = 0.26) (Fig. 2, A and B) . The rate of plaque growth in the vehicle group was significantly higher relative to that in the citalopram group (P = 0.0003). Plaques were classified as regressing in size (<0.75-fold growth), unchanged (0.75-to 1.25-fold growth), or growing (>1.25-fold growth). Citalopram reduced the likelihood of plaque growth [odds ratio (OR), 0.298; 95% confidence interval (CI), 0.148 to 0.600; P = 0.0008] but did not increase the likelihood of plaque regression (OR, 2.1; 95% CI, 0.96 to 4.7; P = 0.063) (Fig. 2C) . Furthermore, citalopram treatment reduced the number of newly appearing plaques [mean, 2.2 (SE, 1.1) versus 10 (SE, 3.9); P = 0.01] but had no effect on the number of disappearing plaques [mean, 3.7 (SE, 1.1) versus 3.6 (SE, 1.5); P = 0.93] (Fig. 2D) . A similar effect on amyloid angiopathy progression was observed [mean, 1.2 (SE, 0.2) versus 2.9 (SE, 0.8); P = 0.03] during 28 days of treatment (Fig. 2E) . Together, these results suggest that citalopram reduces plaque appearance and growth, but has no effect on plaque regression. These effects are consistent with citalopram's inhibition of Ab production without enhancing Ab clearance mechanisms. The mean concentration of ISF Ab x-40 at hours 21 to 24 after drug administration was 103, 105.8, 87.6, 75.5, and 72.5% (mean % ± SE 3.56) for vehicle and ascending doses of citalopram, respectively, compared to baseline in each mouse. There was a significant reduction in ISF Ab at citalopram doses of 5, 10, and 20 mg/kg compared to vehicle-treated mice (*P = 0.003, **P < 0.001, and ***P < 0.0001, respectively). Ab concentrations after citalopram (10 mg/kg) were significantly lower than for citalopram (5 mg/kg) (P = 0.02) but did not differ significantly from the dose of 20 mg/kg. ns, not significant.
Citalopram reduces CSF Ab production and concentrations in humans Healthy subjects with age 18 to 50 years, without medical disease, electrocardiogram, or laboratory abnormalities and with no previous history of antidepressant treatment, were enrolled in a double-blind study. Forty volunteers were screened for inclusion and exclusion criteria; 12 were screen failures. Among the 28 enrolled subjects, 4 had no obtainable CSF and 1 subject was not included in the analysis because the citalopram dose occurred later than other subjects; diurnal variation in Ab concentrations precluded adjusting the "start" time for measurement (18) .
Three subjects had post-lumbar puncture headaches, and their participation had to be halted during the study. Adverse events included eight (33%) post-lumbar puncture headaches requiring an epidural blood patch (a treatment for lumbar puncture-induced headaches), two episodes (8%) of back and leg pain, and four episodes (16%) of nausea and vomiting. One subject received Compazine because of nausea. All events resolved and likely were related to lumbar CSF sampling or the high dose of citalopram used in this study. Of these side effects, nausea and vomiting were most likely due to the SSRI. Twenty-three subjects (11 females and 12 males) had measurements taken of CSF Ab concentrations and 13 C-labeled (newly produced) and unlabeled (residual) Ab. The placebo-versus citalopram-treated volunteers included in the analysis did not differ in demographic characteristics, including age, gender, or race. Placebo-and citalopram-treated volunteers were first matched on gender and then as closely as possible in age, always within 5 years. In addition, because the groups were not explicitly matched on race, at study midpoint, the groups were checked by an unblinded research assistant to ensure that they were balanced in racial composition.
Hourly CSF sampling began 8 hours after initial treatment with citalopram or placebo. Thirteen subjects had CSF sampling for 37 hours, and 10 subjects had CSF sampling for 18 hours, which includes the 12-hour production phase [see Bateman et al. for description of the incorporation of 13 C-labeled leucine as a measure of "newly generated," that is, newly produced, Ab (19, 20) ]. Citalopram-treated subjects had significantly different changes in Ab concentrations over time compared to placebo (repeated-measures ANOVA: time by treatment group, P = 0.002), along with a significant main effect of the treatment group (P = 0.001) (Fig. 3A) . Post hoc approximate t tests revealed significant differences (P < 0.05) between the treatment and placebo groups in terms of change in the mean Ab concentrations from baseline and at hours 10, 13 to 16, 19, 22 to 27, 29, 32 to 41, and 44 to 45 from treatment. Citalopram treatment was associated with a 38% lower average Ab concentration over the 37-hour sampling period compared to placebo (P = 0.001) (Fig. 3B) . The longitudinal change in concentrations of newly produced Ab, as assessed by plasma [ 13 C 6 ]leucine normalized labeled Ab, also differed significantly between citalopramtreated subjects relative to placebo (time by treatment group, P = 0.0004), along with a significant main effect of treatment group (P = 0.008) (Fig. 3C) . As with Ab concentrations, newly produced Ab was reduced in citalopram-treated individuals, because post hoc approximate t tests revealed that the change in average concentration of newly generated Ab from baseline was significantly lower in the citalopram-treated group relative to placebo at hours 13 to 41 and 44 to 45 (P < 0.05). The mean production rate of Ab within CSF calculated over hours 13 to 22 was significantly lower in citalopram-treated individuals (mean, 1.33 pg/hour; SE, 0.15) versus placebo (mean, 2.11 pg/hour; SE, 0.20; P = 0.005), a reduction of 37%. However, the clearance rate of Ab was unchanged [mean, −0.61 (SE, 0.14) versus −0.96 (SE, 0.16) per hour mean and 95% CI; P = 0.115]. These data suggest that citalopram reduced CSF Ab concentrations by suppressing Ab production while having a negligible effect on Ab clearance mechanisms. The tracer/tracee ratio (labeled Ab/unlabeled Ab) (TTR) over the 37 hours of CSF sampling was overlapping for both groups ( fig. S2 ), suggesting that the fractional turnover of Ab was unchanged at the time of the SILK study and that Ab metabolism had reached a new steady state. The longitudinal course of TTR was not significantly different between the two groups (time by treatment group, P = 0.99; main effect of treatment group, P = 0.91).
DISCUSSION
In a prospective study of CSF measurements, we show that an acute dose of citalopram administration was associated with a decreased amount of newly generated Ab in young healthy humans and decreased CSF Ab concentrations compared with placebo. This effect was seen in the production phase of Ab with no significant group differences initially, but with subsequent differences that remained throughout the production phase and with no effect on clearance. In complementary rodent studies, we used serial twophoton imaging and found that administration of citalopram prospectively blocked the growth of existing amyloid plaques and significantly reduced the appearance of new plaques, compared to vehicle-treated animals, over a 4-week period. We have previously shown in mice that SSRI antidepressants lower the production of Ab by 25% in the brain ISF, as demonstrated by in vivo microdialysis studies (13) . To date, this effect has been determined for four different SSRI antidepressants. We have now demonstrated a dose-response curve for the effects of citalopram on lowering Ab concentrations in plaquebearing mice. The maximal effective dose of citalopram that lowered brain Ab concentrations and plaques in mice (10 mg/kg) is approximately comparable to a dose of citalopram (50 mg/day) that has been administered to humans as an antidepressant, and similar to the dose we used in this study, 60 mg. Further, we previously showed in retrospective studies in humans that SSRI exposure within the 5 years before amyloid PET scan was associated with lower amyloid binding as determined by PIB-PET imaging (13) . A recently discovered protective mutation in APP (A673T) has approximately the same magnitude of Ab-lowering effect as the citalopram effect in the current study, strengthening the argument for SSRIs as a potential AD prevention strategy (21) .
There is an interesting discrepancy in the timing of the response to SSRI treatment for depression compared with the current study. Depression therapy generally takes several weeks of SSRI treatment before amelioration of symptoms occurs. However, we see reductions in CSF Ab within a matter of hours. The mechanisms by which SSRIs mediate these two effects are likely to be very different. Current theories for SSRI-mediated treatment of depression include increased production of brain-derived neurotrophic factor (22) , increased hippocampal neurogenesis (23) (24) (25) , and reduced expression of serotonin autoreceptors (26) . All of these processes require weeks to take full effect. In contrast, the mechanisms that regulate Ab production use direct signaling pathways, which exert their effects much faster. Stimulation of serotonin receptors activates the extracellular signal-regulated kinase (ERK) signaling cascade in as little as 5 min (27-29). Our previous studies demonstrated that ERK activation was required for serotonin-dependent suppression of Ab (13) . After citalopram treatment in mice, we also found increased a-secretase activity, which appears to be downstream of ERK signaling (30) . ERK activity can also reduce g-secretase activity, which would lower Ab levels. Adding activated ERK to an in vitro g-secretase cleavage assay reduced activity in a dose-dependent manner, and the g-secretase subunit nicastrin is an ERK substrate (31) . Phosphorylation of either of these secretase enzymes by activated ERK could occur within minutes of SSRI treatment, thus accounting for the rapid changes in Ab levels. Future experiments are still necessary to further define the entire intracellular signaling pathway responsible for the reduced Ab production after SSRI treatment.
Maintaining low Ab concentrations with any agent, including secretase inhibitors or SSRIs, should limit the rate at which toxic species of Ab are formed. Early in disease pathogenesis, soluble Ab monomers aggregate into soluble Ab oligomers and insoluble Ab plaques, both of which can alter synaptic transmission and be toxic to neurons under certain conditions. Conversion of Ab from its normal soluble form into these toxic conformations is concentration-dependent; high concentrations of Ab are much more prone to aggregate than lower concentrations of Ab (7). Small changes in CSF Ab concentration have marked effects on Ab accumulation as plaques. In animal models, a 12 to 25% reduction in Ab concentrations was sufficient to markedly decrease plaque formation (32) . In studies using BACE knockout mice, a 12% decrease in Ab concentrations, assessed in total brain tissue, resulted in a marked blocking of plaque formation (33) . Here, a decrease of 25% in Ab concentration produced a 78% reduction in new plaque formation. Individuals with autosomal dominant AD or Down syndrome have only 20 to 50% higher CSF Ab 42 concentrations than normal but manifest disease 20 to 30 years before AD patients with the sporadic form of the disease. Therefore, development of safe and effective therapeutic approaches that can reduce CNS Ab concentrations even modestly may prevent pathological amyloid accumulation and a subsequent cascade of neuronal damage, which would have an important impact on preventing or slowing progression to symptomatic AD. The ability to decrease CNS Ab concentrations is thus potentially important as a preventive strategy for AD. A caveat is that there have been clinical trials in AD and mild cognitive impairment using Ab-lowering drugs that were unsuccessful. However, these trials were conducted after the onset of clinical symptoms and thus may have been too late to prevent further disease progression. Nonetheless, the efficacy of the current proposed prevention strategy depends critically on the validity of the amyloid hypothesis of AD.
A limitation of the study is that data were not collected during the 8 hours after drug/placebo administration. Thus, an important unanswered question is the timing of when CSF concentration differences arose. The concentrations over the time course were such that steadystate kinetics applied reasonably well after the first 12 hours and the rate of change of concentration appeared similar in both groups. Tracer kinetics established that the fractional turnover rate in the two groups was very similar, suggesting that Ab metabolism had reached a new steady state at the time when the SILK study was carried out. In future studies, it will still be important to establish that the change in concentrations occurred as a result of drug administration.
Another limitation is that our human studies were conducted in young individuals, presumably before plaque formation. It is not known whether the same effect would be observed in older individuals with plaque deposition. However, the current dose-response studies and prospective plaque visualization studies in older mice (with plaques) suggest that the Ab-lowering effects of citalopram likely will be effective in older amyloid plaque-positive humans. The next step will be prospective trials in older cognitively normal individuals to test the ability of SSRI exposure to prevent the development or slow the growth of plaques and thus the subsequent cascade to dementia.
MATERIALS AND METHODS

Study design
The overall objective of the study was to determine in mouse AD models and in young healthy human volunteers whether citalopram had an amyloid protein-lowering effect in brain ISF and CSF, respectively. In mice, this was assessed by dose-response curve microdialysis studies on amyloid concentrations and by multiphoton microscopy determination of individual plaque growth. In humans, this was assessed by determining the amyloid production rate and CSF concentrations in double-blind randomized studies of citalopram versus placebo. Predicting a 25% drop in Ab after administration of citalopram (estimated from our preliminary mouse data) and assuming a 10% SD from previous work, we estimated that with 10 subjects per group, we would have >80% power at an a of 0.05 to detect differences between drug and placebo.
Mouse studies All experimental procedures involving animals were performed in accordance with guidelines established by the Animal Studies Committee at Washington University. We bred APP/PS1 +/− hemizygous mice (34) to wild-type C3H/B6 mice (The Jackson Laboratory) and then used the APP/PS1 +/− offspring for experiments at 12 months of age, when this model contains ample Ab deposits throughout the hippocampus and cortex. These mice contain a PS1DE9 mutation and human APP Swedish mutation that were inserted into a single locus. Animals were screened for the PS1 and APP transgenes by polymerase chain reaction from tail DNA. Male and female littermate mice were distributed between all experimental groups. For multiphoton studies, 6-month-old mice were injected intraperitoneally daily with either citalopram (10 mg/kg) or saline for 28 days. Multiphoton imaging was performed on the day before the first injection and after the last injection (see below).
In vivo Ab microdialysis
In vivo microdialysis to assess brain ISF Ab in the hippocampus of awake, freely moving APP/PS1 +/− mice was performed similar to previously described (13, 35) . This technique samples soluble molecules within the extracellular fluid that are smaller than 38 kD, the molecular weight cutoff (MWCO) of the probe membrane. Ab capable of entering the probe has been dubbed "exchangeable Ab or eAb."
Under isoflurane volatile anesthetic, guide cannulae (BR style, Bioanalytical Systems) were cemented into the left hippocampus (3.1 mm behind bregma, 2.5 mm lateral to midline, and 1.2 mm below dura at a 12°angle). Two-millimeter microdialysis probes were inserted through the guides so the membrane was contained entirely within the hippocampus (BR-2, 30-kD MWCO membrane, Bioanalytical Systems). Microdialysis perfusion buffer was artificial CSF (1.3 mM CaCl 2 , 1.2 mM MgSO 4 , 3 mM KCl, 0.4 mM KH 2 PO 4 , 25 mM NaHCO 3 , and 122 mM NaCl, pH 7.35) containing 4% bovine serum albumin (Sigma) that was filtered through a 0.1-mm membrane. Flow rate was a constant 1.0 ml/min. Samples were collected every 90 min with a refrigerated fraction collector into polypropylene tubes and assessed for Ab x-40 by enzyme-linked immunosorbent assay (ELISA) at the completion of each experiment. Basal concentrations of ISF Ab were defined as the mean concentration of Ab over the 8 hours preceding drug treatment. Once basal ISF Ab concentrations were established, APP/PS1 mice were administered either vehicle (PBS) or citalopram at one of four doses intraperitoneally (2.5, 5, 10, and 20 mg/kg). After drug treatment, ISF Ab concentrations were sampled every 90 min for an additional 24 hours, and then, all samples were assayed for Ab concentration by sandwich ELISA. All ISF Ab concentrations were normalized to the basal Ab concentration in each mouse.
Ab sandwich ELISA ISF Ab concentrations were assessed using sandwich ELISAs as described (13) . Briefly, a mouse anti-Ab 40 antibody (mHJ2) was used to capture and a biotinylated central domain antibody (mHJ5.1) was used to detect, followed by streptavidin-poly-HRP40 (Fitzgerald Industries). All ELISA assays were developed using Super Slow ELISA TMB (Sigma), and absorbance was read on a Bio-Tek Epoch plate reader at 650 nm. The standard curve for each assay used synthetic human Ab 1-40 peptide (American Peptide).
Thinned-skull cranial window surgery Thinned-skull cranial windows were prepared on the day of the first multiphoton imaging session as described previously (32) . Briefly, mice were anesthetized under volatile isoflurane, and the skin and periosteum were removed to expose the skull. A high-speed drill and a microsurgical blade (Surgistar) were used to thin the skull until the skull was transparent and displayed flexibility. Two thinned-skull windows (each 0.8 to 1.0 mm in diameter) were prepared on each animal.
In vivo multiphoton microscopy
Longitudinal multiphoton microscopy to monitor amyloid plaque growth was performed as described previously (3). Briefly, mice were injected intraperitoneally with the fluorescent amyloid-binding compound methoxy-X04 (5 mg/ml) 24 hours before each multiphoton imaging session (36) . Animals were mounted on a custom-built stereotaxic apparatus, and a small ring of molten bone wax was applied to the skull surrounding the perimeter of the window to create a water immersion chamber. The cranial window was centered under the objective lens on a two-photon microscope [LSM 510 META NLO system (Carl Zeiss Inc.) with a Chameleon Ti:Sapphire laser (Coherent Inc.)]. Two-photon fluorescence was generated with 750-nm excitation, and fluorescence emission was detected at 435 to 485 nm. A 10× water immersion objective [numerical aperture (NA) = 0.33, Zeiss] was used to create a site map during initial imaging, and a 40× water immersion objective (NA = 0.75, Zeiss) was used for high-resolution quantification of individual amyloid plaques. Incremental z-stack image series (step distance = 10 and 5 mm under 10× and 40× objectives, respectively) were acquired from the skull surface to about 200 mm into cortex.
To determine the effect of citalopram on amyloid plaque formation and growth, the same sites for each animal were imaged on days 0 and 28. Collapsed z-stack images for each individual plaque were measured by radii of plaque and intensity using SigmaScan Pro Image Analysis Software (Systat Software) with a preset threshold (threshold = mean + 4 × SD). Plaques were excluded from analysis if they were located at the edge of the window and exhibited fluorescence intensity less than the mean intensity of an adjacent background region or if the image acquisition was affected by motion artifacts from heartbeat or respiration.
Human studies A randomized double-blind placebo-controlled study was performed to determine the CNS effect of 60 mg of the SSRI antidepressant citalopram, given in divided oral doses (two doses of 30 mg each). This study was approved by the Washington University Human Studies Committee, and all participants gave written consent. Healthy 21-to 50-year-old male and female volunteers were invited to participate, screened, and enrolled. Exclusion criteria included any serious or unstable medical illness including neurologic disease and previous use of antidepressants within the past 5 years. Each participant received either placebo or a dose of 30 mg of citalopram 8 and 6 hours before the start of the labeling study (total = 60 mg). A CNS stable isotope labeling kinetics study of Ab was conducted, as previously described (19) . Briefly, after an overnight fast, a lumbar subarachnoid catheter was placed at the L3-L4 interspace, intravenous catheters were placed in both arms, and hourly sampling of blood and CSF was conducted during and after administration of a stable isotope-labeled amino acid ([ 13 C 6 ]leucine) (19, 20) . Serial samples of 12 ml of blood and 6 ml of CSF were taken at 1-hour time intervals for up to 37 hours. CSF has a production rate of 20 ml per hour and replenishes itself throughout the procedure. We administered [ 13 C 6 ]leucine with an initial bolus of 2 mg/kg over 10 min, followed by 9 hours of continuous intravenous infusion at a rate of 2 mg/kg per hour. Participants were provided with three low-leucine diet meals during the leucine infusion to decrease the amount of ingested unlabeled leucine. Participants rested overnight after the study with discharge at 48 hours.
Labeled and unlabeled Ab analysis by MS Incorporation of [ 13 C 6 ]leucine into Ab was measured using the stable isotope labeling kinetics (SILK-Ab) assay similar to Bateman et al. (19) , with the addition of stable isotope spike absolute quantitation (SISAQ) to allow for absolute quantitation of Ab in the samples (C2N Diagnostics).
A quantitation peptide (Ab 40 ) was added to all samples at a final concentration of 10 ng/ml before immunoprecipitation of Ab from the sample. Ab was immunoprecipitated using the Ab mid-domain-specific antibody HJ5.1 (37) ]leucine enrichment was quantified using capillary gas chromatography-MS (GC-MS) as described (20) . Plasma leucine was converted to its heptafluorobutyric propyl ester, and the [ 9 ). Citalopram has a long half-life, meaning there was likely a sustained effect on Ab throughout CSF sampling despite the single administration at the beginning of the study.
Statistics
Repeated-measures ANOVA (38) with fixed effects of treatment group, time and a treatment group by time interaction, was used to analyze the patterns of change in basal ISF Ab, plaque growth, newly generated Ab, Ab concentrations, and TTR over time. To account for the withinsubject dependencies in the outcome variables, these models incorporated a random intercept at the subject level and, for plaque growth, also a random intercept at the plaque level. The models also incorporated a Toeplitz covariance structure for the model errors in basal ISF Ab, first-order autoregressive process heterogeneous variance-covariance structure for the model errors in newly generated Ab, and the same covariance structure but with homogeneous variance for CSF concentrations of total Ab and TTR, because these provided the best measures on Akaike's information criterion (39) . Subsequent model-derived post hoc approximate t tests were used to assess differences between treatment groups, at specific time points, in change in the mean concentrations of newly generated Ab and Ab concentrations from baseline, whereas, for basal ISF Ab, mean concentrations averaged over hours 21 to 24 were compared.
The production and clearance rates were estimated as the difference in mean newly generated Ab at hours 14 and 5 and 30 and 20, respectively, divided by the number of hours between each pair of measurements. Differences between the production and clearance rates between the treatment groups were tested with model-derived approximate t tests. Admittedly, this model is limited by presuming that production and clearance rates are independent phenomena in the analysis, whereas, practically, production and clearance occur simultaneously.
The general linear mixed models were estimated using restricted maximum likelihood estimation, with the approximate F test denominator degrees of freedom based on the method of Kenward and Roger (40) . The likelihood of plaques exhibiting regression, growth, or remaining unchanged was compared between the treatment groups with a nonproportional odds cumulative logit model. The number of disappearing/appearing plaques was compared between treatment groups using an exact Wilcoxon rank-sum test, with CAA load compared using a t test. All analyses were conducted using SAS version 9.3 (SAS Institute Inc.).
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